Literature DB >> 3404457

Albendazole sulfonation by rat liver cytochrome P-450c.

H Souhaili-El Amri1, O Mothe, M Totis, C Masson, A M Batt, P Delatour, G Siest.   

Abstract

The metabolism of albendazole (ABZ) was studied in perfused livers from control and ABZ-treated rats (10.6 mg/kg, per os, each day for 10 days). In the perfusion fluid, the concentration of ABZ-sulfoxide (SO-ABZ) remained unchanged in treated, as compared to control animals, whereas ABZ-sulfone (SO2-ABZ) was increased in treated animals. In bile, only SO-ABZ was present. The transformation kinetics of SO-ABZ to SO2-ABZ in microsomes from rats treated with ABZ, 3-methylcholanthrene, Aroclor and isosafrole were biphasic. This suggests that enzyme activity was a consequence of two enzyme systems, one characterized by low affinity and high capacity, the other by high affinity and low capacity, the latter could be induced by 3-methylcholanthrene, ABZ, Aroclor and isosafrole. Cytochrome P-450c was induced potently in vivo by ABZ as proven by increased monooxygenase (7-ethoxyresorufin and 7-ethoxycoumarin-O-deethylase) activities and by Elisa test (a 5-fold increase in hemoprotein concentration was observed). Purified and reconstituted cytochrome P-450c from 3-methylcholanthrene or ABZ-treated rat liver were able to produce SO2-ABZ (2.01 and 1.70 nmol/mg/15 min, respectively, whereas cytochrome P-450b produced 10 times less SO2-ABZ). Immunological assays, as well as activity measurements showed a relationship between cytochrome P-450c-3-methylcholanthrene and cytochrome P-450c-ABZ. We conclude that induction of cytochrome P-450c by ABZ is the probable explanation for the enhanced formation of SO2-ABZ in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3404457

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

2.  Efficacy of albendazole and mebendazole against Hymenolepis microstoma and Hymenolepis diminuta.

Authors:  R O McCracken; K B Lipkowitz; N O Dronen
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

3.  CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.

Authors:  Zhexue Wu; Doohyun Lee; Jeongmin Joo; Jung-Hoon Shin; Wonku Kang; Sangtaek Oh; Do Yup Lee; Su-Jun Lee; Sung Su Yea; Hye Suk Lee; Taeho Lee; Kwang-Hyeon Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

4.  Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Authors:  C Gokbulut; V Y Cirak; B Senlik
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

5.  Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

Authors:  H C Rawden; G O Kokwaro; S A Ward; G Edwards
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

6.  Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep.

Authors:  B P Capece; G Castells; F Pérez; M Arboix; C Cristòfol
Journal:  Vet Res Commun       Date:  2000-07       Impact factor: 2.459

7.  Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.

Authors:  O M Takayanagui; P S Bonato; S A C Dreossi; V L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

8.  Aspects of the pharmacokinetics of albendazole sulphoxide in sheep.

Authors:  A Goudah
Journal:  Vet Res Commun       Date:  2003-10       Impact factor: 2.459

Review 9.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

10.  An antioxidant response is involved in resistance of Giardia duodenalis to albendazole.

Authors:  Raúl Argüello-García; Maricela Cruz-Soto; Rolando González-Trejo; Luz María T Paz-Maldonado; M Luisa Bazán-Tejeda; Guillermo Mendoza-Hernández; Guadalupe Ortega-Pierres
Journal:  Front Microbiol       Date:  2015-04-10       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.